Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD

European Respiratory Journal

Volumn 40, Issue 6, 2012, Pages 1344-1353

  Soler, Néstor ^a   Esperatti, Mariano ^a   Ewig, Santiago ^b   Huerta, Arturo ^a   Agusti, Carlos ^a   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Augusta Kranken Anstalt   (Germany)

Author keywords

Antibiotic treatment; C reactive protein; Chronic obstructive pulmonary disease; Procalcitonin; Sputum purulence

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; OXYGEN; PREDNISOLONE; PREDNISONE; PROCALCITONIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DRUG DOSE REDUCTION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSIOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SPUTUM; SUPPURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865639862     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00150211     Document Type: Article

References (32)

1. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining the cause and prevention. Lancet 2007; 370: 786-796. (Pubitemid 47320802)
2. Soler-Cataluña JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931. (Pubitemid 41598207)
3. Donaldson GC, Seemungal TA, Bhowmik A, et al. The relationship between exacerbations frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
4. Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006; 144: 894-903. (Pubitemid 46768129)
5. Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891-897. (Pubitemid 40563235)
6. Sheti S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471. (Pubitemid 34879333)
7. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860. (Pubitemid 351600663)
8. Sheti S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
9. Jørgensen AF, Coolidge J, Pedersen PA, et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10: 7-11.
10. Sachs AP, Koëter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-763.
11. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
12. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150-157.
13. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 15: 2020-2025. (Pubitemid 34084824)
14. Stolz D, Christ-Chrain M, Beingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19. (Pubitemid 46122969)
15. Wenzel RP, Wong MT. Managing antibiotic use: impact of infection control. Clin Infect Dis 1999; 28: 1126-1127. (Pubitemid 29203550)
16. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of drug-multiresistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-1924. (Pubitemid 32064785)
17. Wenzel RP. The antibiotic pipeline: challenges, costs, and values. N Engl J Med 2004; 351: 523-526.
18. Guillemot D, Courvalin P. Better control of antibiotic resistance. Clin Infect Dis 2001; 33: 542-547. (Pubitemid 32709588)
19. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645. (Pubitemid 30413357)
20. Soler N, Agusti C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35. (Pubitemid 46101763)
21. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.com Date last accessed: April 8, 2010. Date last updated: 2009.
23. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947. (Pubitemid 29288269)
24. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clinic Proc 1975; 50: 339-344.
25. Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007; 55: 226-232. (Pubitemid 47244922)
26. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103: 601-606.
27. Stolz D, Christ-Crain M, Morgenthaler N, et al. Copeptin, Creactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067. (Pubitemid 46608707)
28. Singh D, Edwards L, Tal-Singer R, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010; 11: 77.
29. Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 491-497. (Pubitemid 351442187)
30. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361. (Pubitemid 47267469)
31. Agency for Healthcare Research and Quality HCUPnet: Healthcare Cost and Utilization Project. www.ahrq.gov/HCUPnet
32. Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010; 303: 203.